Comparison of microbiological profile of enterotoxigenic Bacteroides fragilis (ETBF) isolates from subjects with colorectal cancer (CRC) or intestinal pre-cancerous lesions versus healthy individuals and evaluation of environmental factors involved in intestinal dysbiosis.


Journal

Anaerobe
ISSN: 1095-8274
Titre abrégé: Anaerobe
Pays: England
ID NLM: 9505216

Informations de publication

Date de publication:
Aug 2023
Historique:
received: 27 03 2023
revised: 14 06 2023
accepted: 20 06 2023
medline: 4 10 2023
pubmed: 29 6 2023
entrez: 28 6 2023
Statut: ppublish

Résumé

The aim of this study was to analyze enterotoxigenic Bacteroides fragilis (ETBF) isolates from colorectal biopsies of subjects with a histological analysis positive for colorectal cancer (CRC), pre-cancerous lesions (pre-CRC) or with a healthy intestinal tissue and to evaluate the environmental factors that may not only concur to CRC development but may also affect gut microbiota composition. ETBF isolates were typed using the ERIC-PCR method, while PCR assays were performed to investigate the bft alleles, the B. fragilis pathogenicity island (BFPAI) region and the cepA, cfiA and cfxA genes. Susceptibility to antibiotics was tested using the agar dilution method. Environmental factors that could play a role in promoting intestinal dysbiosis were evaluated throughout a questionnaire administered to the subjects enrolled. Six different ERIC-PCR types were identified. The type denominated C in this study was the most prevalent, in particular among the biopsies of subjects with pre-CRC, while an isolate belonging to a different type, denominated F, was detected in a biopsy from a subject with CRC. All the ETBF isolates from pre-CRC or CRC subjects had a B. fragilis pathogenicity island (BFPAI) region pattern I, while those from healthy individuals showed also different patterns. Furthermore, 71% of isolates from subjects with pre-CRC or CRC were resistant to two or more classes of antibiotics vs 43% of isolates from healthy individuals. The B. fragilis toxin BFT1 was the most frequently detected in this study, confirming the constant circulation of this isoform strains in Italy. Interestingly, BFT1 was found in 86% of the ETBF isolates from patients with CRC or pre-CRC, while the BFT2 was prevalent among the ETBF isolates from healthy subjects. No substantial differences based on sex, age, tobacco and alcohol consumption were observed between healthy and non-healthy individuals included in this study, while most of the subjects with CRC or pre-CRC lesions were subjected to pharmacological therapy (71%) and showed a body mass index (BMI) that falls within the overweight range (86%). Our data suggest that some types of ETBF seem to better adapt and colonize the human gut and that the selective pressure exerted by factors related to lifestyle, such as pharmacological therapy and weight, could facilitate their persistence in the gut and their possible involvement in CRC development.

Identifiants

pubmed: 37380012
pii: S1075-9964(23)00066-5
doi: 10.1016/j.anaerobe.2023.102757
pii:
doi:

Substances chimiques

Bacterial Toxins 0
Metalloendopeptidases EC 3.4.24.-
Anti-Bacterial Agents 0

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

102757

Informations de copyright

Copyright © 2023 Elsevier Ltd. All rights reserved.

Déclaration de conflit d'intérêts

Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Auteurs

Patrizia Spigaglia (P)

Department of Infectious Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy. Electronic address: patrizia.spigaglia@iss.it.

Fabrizio Barbanti (F)

Department of Infectious Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy. Electronic address: fabrizio.barbanti@iss.it.

Elena Angela Pia Germinario (EAP)

Department of Cardiovascular, Endocrine-Metabolic Diseases and Ageing, Istituto Superiore di Sanità, 00161, Rome, Italy. Electronic address: elena.germinario@iss.it.

Enrico Maria Criscuolo (EM)

Department of Infectious Diseases, Istituto Superiore di Sanità, 00161, Rome, Italy. Electronic address: enrico.criscuolo@guest.iss.it.

Giovanni Bruno (G)

Department of Translational and Precision Medicine, Gastroenterology Unit, Policlinic Umberto I, University of Rome 'Sapienza', 00161, Rome, Italy. Electronic address: giovanbru@gmail.com.

Lupe Sanchez-Mete (L)

Gastroenterology and Digestive Endoscopy IRCCS Regina Elena National Cancer Institute, 00144, Rome, Italy. Electronic address: lupe.sanchez@ifo.gov.it.

Barbara Porowska (B)

Digestive Endoscopy UOC CSC03 of the Department of General Surgery, Surgical Specialities "Paride Stefanini", Policlinic Umberto I, University of Rome 'Sapienza', 00161, Rome, Italy. Electronic address: barbara.porowska@uniroma1.it.

Vittoria Stigliano (V)

Gastroenterology and Digestive Endoscopy IRCCS Regina Elena National Cancer Institute, 00144, Rome, Italy. Electronic address: vittoria.stigliano@ifo.gov.it.

Fabio Accarpio (F)

Digestive Endoscopy UOC CSC03 of the Department of General Surgery, Surgical Specialities "Paride Stefanini", Policlinic Umberto I, University of Rome 'Sapienza', 00161, Rome, Italy. Electronic address: fabio.accarpio@gmail.com.

Andrea Oddi (A)

Hepatopancreatobiliary Surgery, IRCCS Regina Elena National Cancer Institute, 00114, Rome, Italy. Electronic address: andrea.oddi@ifo.gov.it.

Ilaria Zingale (I)

Digestive Endoscopy UOC CSC03 of the Department of General Surgery, Surgical Specialities "Paride Stefanini", Policlinic Umberto I, University of Rome 'Sapienza', 00161, Rome, Italy. Electronic address: ilaria88zingale@gmail.com.

Silvia Rossi (S)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161, Rome, Italy. Electronic address: silvia.rossi@iss.it.

Roberta De Angelis (R)

Department of Oncology and Molecular Medicine, Istituto Superiore di Sanità, 00161, Rome, Italy. Electronic address: roberta.deangelis@iss.it.

Alessia Fabbri (A)

Department of Cardiovascular, Endocrine-Metabolic Diseases and Ageing, Istituto Superiore di Sanità, 00161, Rome, Italy. Electronic address: alessia.fabbri@iss.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH